The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033

The optimal treatment for patients with low-grade glioma (LGG) WHO grade II remains controversial. Overall survival ranges from 2 to over 15 years depending on molecular and clinical factors. Hence, risk-adjusted treatments are required for optimizing outcome and quality of life. We aim at identifyi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Bady, Pierre (VerfasserIn) , Wick, Wolfgang (VerfasserIn) , Deimling, Andreas von (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 24 January 2018
In: Acta neuropathologica
Year: 2018, Jahrgang: 135, Heft: 4, Pages: 601-615
ISSN:1432-0533
DOI:10.1007/s00401-018-1810-6
Online-Zugang:Verlag, Volltext: https://doi.org/10.1007/s00401-018-1810-6
Volltext
Verfasserangaben:Pierre Bady, Sebastian Kurscheid, Mauro Delorenzi, Thierry Gorlia, Martin J. van den Bent, Khê Hoang-Xuan, Élodie Vauléon, Anja Gijtenbeek, Roelien Enting, Brian Thiessen, Olivier Chinot, Frédéric Dhermain, Alba A. Brandes, Jaap C. Reijneveld, Christine Marosi, Martin J.B. Taphoorn, Wolfgang Wick, Andreas von Deimling, Pim French, Roger Stupp, Brigitta G. Baumert, Monika E. Hegi

MARC

LEADER 00000caa a2200000 c 4500
001 1691312649
003 DE-627
005 20240404193256.0
007 cr uuu---uuuuu
008 200302s2018 xx |||||o 00| ||eng c
024 7 |a 10.1007/s00401-018-1810-6  |2 doi 
035 |a (DE-627)1691312649 
035 |a (DE-599)KXP1691312649 
035 |a (OCoLC)1341308765 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Bady, Pierre  |e VerfasserIn  |0 (DE-588)1205686428  |0 (DE-627)1691313122  |4 aut 
245 1 4 |a The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033  |c Pierre Bady, Sebastian Kurscheid, Mauro Delorenzi, Thierry Gorlia, Martin J. van den Bent, Khê Hoang-Xuan, Élodie Vauléon, Anja Gijtenbeek, Roelien Enting, Brian Thiessen, Olivier Chinot, Frédéric Dhermain, Alba A. Brandes, Jaap C. Reijneveld, Christine Marosi, Martin J.B. Taphoorn, Wolfgang Wick, Andreas von Deimling, Pim French, Roger Stupp, Brigitta G. Baumert, Monika E. Hegi 
264 1 |c 24 January 2018 
300 |a 15 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 02.03.2020 
520 |a The optimal treatment for patients with low-grade glioma (LGG) WHO grade II remains controversial. Overall survival ranges from 2 to over 15 years depending on molecular and clinical factors. Hence, risk-adjusted treatments are required for optimizing outcome and quality of life. We aim at identifying mechanisms and associated molecular markers predictive for benefit from radiotherapy (RT) or temozolomide (TMZ) in LGG patients treated in the randomized phase III trial EORTC 22033. As candidate biomarkers for these genotoxic treatments, we considered the DNA methylome of 410 DNA damage response (DDR) genes. We first identified 62 functionally relevant CpG sites located in the promoters of 24 DDR genes, using the LGG data from The Cancer Genome Atlas. Then we tested their association with outcome [progression-free survival (PFS)] depending on treatment in 120 LGG patients of EORTC 22033, whose tumors were mutant for isocitrate dehydrogenase 1 or 2 (IDHmt), the molecular hallmark of LGG. The results suggested that seven CpGs of four DDR genes may be predictive for longer PFS in one of the treatment arms that comprised MGMT, MLH3, RAD21, and SMC4. Most interestingly, the two CpGs identified for MGMT are the same, previously selected for the MGMT-STP27 score that is used to determine the methylation status of the MGMT gene. This score was higher in the LGG with 1p/19q codeletion, in this and other independent LGG datasets. It was predictive for PFS in the TMZ, but not in the RT arm of EORTC 22033. The results support the hypothesis that a high score predicts benefit from TMZ treatment for patients with IDHmt LGG, regardless of the 1p/19q status. This MGMT methylation score may identify patients who benefit from first-line treatment with TMZ, to defer RT for long-term preservation of cognitive function and quality of life. 
700 1 |a Wick, Wolfgang  |d 1970-  |e VerfasserIn  |0 (DE-588)120297736  |0 (DE-627)080586929  |0 (DE-576)186221320  |4 aut 
700 1 |a Deimling, Andreas von  |d 1959-  |e VerfasserIn  |0 (DE-588)103034115X  |0 (DE-627)735093946  |0 (DE-576)378138065  |4 aut 
773 0 8 |i Enthalten in  |t Acta neuropathologica  |d Berlin : Springer, 1961  |g 135(2018), 4, Seite 601-615  |h Online-Ressource  |w (DE-627)253389666  |w (DE-600)1458410-4  |w (DE-576)072283092  |x 1432-0533  |7 nnas  |a The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033 
773 1 8 |g volume:135  |g year:2018  |g number:4  |g pages:601-615  |g extent:15  |a The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033 
856 4 0 |u https://doi.org/10.1007/s00401-018-1810-6  |x Verlag  |x Resolving-System  |3 Volltext 
951 |a AR 
992 |a 20200302 
993 |a Article 
994 |a 2018 
998 |g 103034115X  |a Deimling, Andreas von  |m 103034115X:Deimling, Andreas von  |d 910000  |d 912000  |e 910000PD103034115X  |e 912000PD103034115X  |k 0/910000/  |k 1/910000/912000/  |p 18 
998 |g 120297736  |a Wick, Wolfgang  |m 120297736:Wick, Wolfgang  |d 910000  |d 911100  |e 910000PW120297736  |e 911100PW120297736  |k 0/910000/  |k 1/910000/911100/  |p 17 
999 |a KXP-PPN1691312649  |e 3601518325 
BIB |a Y 
SER |a journal 
JSO |a {"id":{"eki":["1691312649"],"doi":["10.1007/s00401-018-1810-6"]},"name":{"displayForm":["Pierre Bady, Sebastian Kurscheid, Mauro Delorenzi, Thierry Gorlia, Martin J. van den Bent, Khê Hoang-Xuan, Élodie Vauléon, Anja Gijtenbeek, Roelien Enting, Brian Thiessen, Olivier Chinot, Frédéric Dhermain, Alba A. Brandes, Jaap C. Reijneveld, Christine Marosi, Martin J.B. Taphoorn, Wolfgang Wick, Andreas von Deimling, Pim French, Roger Stupp, Brigitta G. Baumert, Monika E. Hegi"]},"recId":"1691312649","physDesc":[{"extent":"15 S."}],"title":[{"title":"The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033","title_sort":"DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 02.03.2020"],"origin":[{"dateIssuedDisp":"24 January 2018","dateIssuedKey":"2018"}],"relHost":[{"id":{"zdb":["1458410-4"],"issn":["1432-0533"],"eki":["253389666"]},"title":[{"title_sort":"Acta neuropathologica","title":"Acta neuropathologica"}],"part":{"pages":"601-615","issue":"4","extent":"15","text":"135(2018), 4, Seite 601-615","year":"2018","volume":"135"},"type":{"bibl":"periodical","media":"Online-Ressource"},"language":["eng","ger"],"note":["Gesehen am 02.12.2005"],"origin":[{"publisher":"Springer","dateIssuedKey":"1961","publisherPlace":"Berlin ; Heidelberg","dateIssuedDisp":"1961-"}],"pubHistory":["1.1961/62 -"],"disp":"The DNA methylome of DDR genes and benefit from RT or TMZ in IDH mutant low-grade glioma treated in EORTC 22033Acta neuropathologica","recId":"253389666","physDesc":[{"extent":"Online-Ressource"}]}],"person":[{"family":"Bady","given":"Pierre","role":"aut","display":"Bady, Pierre"},{"given":"Wolfgang","role":"aut","family":"Wick","display":"Wick, Wolfgang"},{"family":"Deimling","given":"Andreas von","role":"aut","display":"Deimling, Andreas von"}]} 
SRT |a BADYPIERREDNAMETHYLO2420